Metformin and pioglitazone combination therapy ameliorate polycystic ovary syndrome through AMPK/PI3K/JNK pathway
Authors:
- 15 December 2017
- journal article
- research article
- Published by Spandidos Publications in Experimental and Therapeutic Medicine
- Vol. 15 (2) , 2120-2127
Abstract
Polycystic ovary syndrome (PCOS) is a common gynecological endocrine disorder, which results in health problems such as menstrual disorders, hyperandrogenism and persistent anovulation. Hyperandrogenism and insulin resistance are the basic characteristics of PCOS. To investigate the combined effect of metformin and pioglitazone on POCS and the potential mechanisms, a rat model of PCOS was established by intramuscular injection of estradiol valerate (EV). The effect of metformin and pioglitazone monotherapy or combination therapy in control rats and PCOS rats was evaluated, involving the testosterone level, follicular development and insulin resistance. The potential mechanism for the therapeutic effect of metformin and pioglitazone on POCS was explored through using three inhibitors of the 5'adenosine monophosphate‑activated protein kinase (AMPK)/phosphoinositide‑3 kinase (PI3K)/c‑Jun N‑terminal kinase (JNK) pathway (Compound C, Wortmannin and SP600125). The results showed that EV‑induced PCOS rats demonstrated hyperandrogenemia, hyperinsulinemia and follicular dysplasia. Metformin or pioglitazone monotherapy significantly suppressed the high level of testosterone, reduced the raised percentage of cystic follicles and primary follicles, promoted the number of early antral follicles, and markedly decreased the high concentration of fasting insulin and homeostatic model assessment for insulin resistance index in PCOS rats. In addition, metformin and pioglitazone combination therapy demonstrated greater efficacy than its individual components. Furthermore, individual or joint treatment with metformin and pioglitazone affected the phosphorylation level of JNK in PCOS rats. Compound C and Wortmannin eliminated the effect of metformin and pioglitazone combination therapy on improving the follicular growth in PCOS rats, whereas SP600125 treatment enhanced this combination therapy effect. These data suggested that metformin and pioglitazone combination therapy demonstrated great efficacy in ameliorating PCOS through regulating the AMPK/PI3K/JNK pathway.Keywords
This publication has 46 references indexed in Scilit:
- Metformin and gonadotropins for ovulation induction in patients with polycystic ovary syndrome: a systematic review with meta-analysis of randomized controlled trialsReproductive Biology and Endocrinology, 2014
- Is Insulin Resistance an Intrinsic Defect in Asian Polycystic Ovary Syndrome?Yonsei Medical Journal, 2013
- Effects of metformin in women with polycystic ovary syndrome treated with gonadotrophins for in vitro fertilisation and intracytoplasmic sperm injection cycles: a systematic review and meta‐analysis of randomised controlled trialsBJOG: An International Journal of Obstetrics & Gynaecology, 2012
- Phenotype and Metabolic Disorders in Polycystic Ovary SyndromeISRN Endocrinology, 2012
- A prospective randomized trial comparing the efficacy of Letrozole and Clomiphene citrate in induction of ovulation in polycystic ovarian syndromeJournal of Human Reproductive Sciences, 2012
- Pioglitazone for Diabetes Prevention in Impaired Glucose ToleranceNew England Journal of Medicine, 2011
- Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespanBMC Medicine, 2010
- Human GSTA1-1 reduces c-Jun N-terminal kinase signalling and apoptosis in Caco-2 cellsBiochemical Journal, 2006
- Time of initiation of clomiphene citrate and pregnancy rate in polycystic ovarian syndromeInternational Journal of Gynecology & Obstetrics, 2006
- Insulin receptor binding to monocytes, insulin secretion, and glucose tolerance following metformin treatment. Results of a double-blind cross-over study in type II diabeticsDiabetes, 1983